US20060062755A1 - Method of cancer screening; method of cancer treatment; and method of diabetes treatment - Google Patents
Method of cancer screening; method of cancer treatment; and method of diabetes treatment Download PDFInfo
- Publication number
- US20060062755A1 US20060062755A1 US11/032,399 US3239905A US2006062755A1 US 20060062755 A1 US20060062755 A1 US 20060062755A1 US 3239905 A US3239905 A US 3239905A US 2006062755 A1 US2006062755 A1 US 2006062755A1
- Authority
- US
- United States
- Prior art keywords
- cream
- administering
- aldara
- cancer
- necrosis factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a continuation application of application Ser. No. ______ filed Dec. 3, 2004 (our file 120175-1005), currently pending, which is a which is continuation-in-part application of application Ser. No. 10/946,213 filed Sep. 21, 2004, currently pending.
- This invention relates generally to the detection and treatment of cancers, and more particularly to a method of screening for and a method of treating duct cell cancer of the breast, squamous cell cancer of the uterine cervix, anal cancer, diabetes, and multiple sclerosis.
- As is well known, various technologies are available to the medical profession for use in determining the presence of cancers in patients. Included are x-ray studies, magnetic resonance imaging (MRI) studies, CT scans, as well as studies of various body fluids such as blood, urine, etc. Potential sites for colon cancer, for example, can be investigated utilizing electro-optical technologies. In some cases needle biopsy or exploratory surgery is necessary to confirm either the presence or absence of suspected cancer.
- Various techniques for treating cancers are also well known. Certain cancers can be surgically removed, whereas other cancers require radiation therapy, chemotherapy, or combinations of radiation therapy and chemotherapy. Other cancers are susceptible to control using one or more drug therapies.
- Type I diabetes is generally diagnosed in juveniles and young adults. In type I diabetes, the pancreas does not make insulin, which is necessary for the body to process sugars. Persons with Type I diabetes can live long, healthy lives, but must be careful with their diet and must take insulin to manage their blood glucose levels. Currently, the only treatment for Type I diabetes is to take insulin, or receive pancreas or islet cell transplants.
- Multiple sclerosis (MS) is a chronic, unpredictable disease of the nervous system that afflicts over 2.5 million persons worldwide. An MS attack destroys myelin, the protective fibers around nerve fibers in the central nervous system. The destroyed myelin is replaced by scars of hardened “sclerotic” tissue, and some nerve endings are permanently severed. The common symptoms are loss of balance, fatigue, poor circulation, slurred speech, blindness, and in some cases paralysis. Currently, the only treatment is disease-modifying drugs, including drugs with a chemotherapeutic agent. These treatments only modify the disease to lessen the severity or frequency of the MS attacks.
- The present invention comprises a method of cancer screening, a method of cancer treatment, a method for treatment of diabetes, and a method for treatment of multiple sclerosis which has proven successful in controlling epidermal cancers including, but not limited to, duct cell breast cancer, cervical squamous cancer, and anal cancer, controlling Type I diabetes, and controlling multiple sclerosis. In accordance with the broader aspects of the invention, a method of cancer screening involves a series of testing procedures each more expensive than the one before. Only when results of each of the testing procedures are positive is the presence of cancer confirmed. The invention further comprises a method of treating cancer and insulin dependent Type I diabetes wherein the drug imiquimod is administered transdermally in conjunction with a vaccine containing tumor necrosis factor, for example the BCG vaccine, and valacyclovia hydrochlorine tablets. The method of the present invention treats Type I diabetes by enabling the body to regenerate islet cells. Similarly, multiple sclerosis is managed and treated by enabling the body to repair nerve endings and regenerate damaged fibers.
- A more complete understanding of the present invention may be had by reference to the following Detailed Description when taken in connection with the accompanying Drawings, wherein:
-
FIG. 1 is a flowchart illustrating initial steps in the cancer screening method of the present invention; -
FIG. 2 is a flowchart illustrating subsequent steps in the cancer screening method of the present invention; and -
FIG. 3 is a flowchart illustrating the diabetes treatment method of the present invention. - The following examples describe a method of detecting and treating duct cell breast cancer, and a method for treating Type I diabetes. However, the present invention is equally applicable to other epidermal cancers, such as squamous cancer of the uterine cervix and anal cancer, and the treatment of and management of multiple sclerosis.
- Referring to the Drawings, and particularly to
FIG. 1 thereof, the early steps in the method of cancer screening of the present invention are shown therein. Screening begins with administration of the testing procedure known as Blood CA 27,29. The Blood CA 27,29 testing procedure has heretofore been utilized in monitoring the results of existing cancer treatment procedures. However, the Blood CA 27,29 procedure has not heretofore been used for cancer screening. - If the number comprising the results of the Blood CA 27,29 procedure is less than 20, and if there has been no increase in the number comprising the result of the Blood CA 27,29 testing procedure of ten (10) or more in the immediately preceding year, the result of the Blood CA 27,29 testing procedure is considered to be negative. The patient is then scheduled for follow-up testing utilizing the Blood CA 27,29 procedure in one year.
- If the number comprising the result of the Blood CA 27,29 procedure is 20 or above, or if there has been an increase of 10 or more in the number comprising the result of the CA 27,29 testing procedure in the immediately preceding year, the result of the Blood CA 27,29 procedure is considered to be positive. In that event a mammogram testing procedure is administered. If the result of the mammogram testing procedure is negative, an MRI testing procedure is administered. If the result of the MRI testing procedure is negative, both the mammogram testing procedure and the Blood CA 27,29 testing procedure are re-administered in six months time. Conversely, if either the mammogram testing procedure is positive or the MRI testing procedure is positive, a needle biopsy of the identified lesion is performed.
- Referring to
FIG. 2 , if the results of the needle biopsy testing procedure are negative, both the mammogram testing procedure and the Blood CA 27,29 testing procedure are re-administered in six months. If the needle biopsy testing procedure is positive, a positron emission tomography (PET) scan testing procedure is administered. If the result of the PET scan testing procedure is negative, the mammogram testing procedure and the Blood CA 27,29 testing procedure are re-administered in six months. If the result of the PET scan testing procedure is positive, a blood tumor cell count testing procedure is administered. If the result of the blood tumor cell count testing procedure is negative, that is, if the number comprising the result of the blood tumor cell count testing procedure is between 0 and 1.5, the blood tumor cell count testing procedure and the Blood CA 27,29 testing procedure are administered at three month intervals. Conversely, if the blood tumor cell count testing procedure is positive, that is, if the number comprising the result of the blood tumor cell count testing procedure is two or above, the cancer treatment procedure of the present invention is administered. - The cancer treatment procedure of the present invention comprises the transdermal administration of the drug imiquimod combined with a vaccine containing tumor necrosis factor and administration of valacyclovia hydrochlorine tablets. Imiquimod is commercially available from 3M Pharmaceuticals under the trademark ALDARA™. A healthy human body produces the protein interferon alpha in response to an infection. Interferon alpha works to coat the infection or virus in order to make the infection or virus vulnerable to the human immune system. Imiquimod, i.e. ALDARA™ cream, turns into interferon alpha once inside the human body, providing the needed interferon alpha not adequately produced by the patient's own body. In accordance with the present invention, ALDARA™ cream 5% is mixed at a 1:1 ratio with H base cream. The ingredients of H base cream are:
-
- water, glycerin, canola oil, stearic acid, cetyl alcohol, PEG-100 stearate, glyceryl stearate, dimethicone, magnesium aluminum silicate, propylene glycol, triethanolamine, polysorbate 60, xanthan gum, bitter almond kernel oil, aloe vera, grape seed extract, wheat germ oil, vitamin E acetate, vitamin A palmitate, Vitamin C palmitate, tetrasodium EDTA, potassium sorbate, diazolidinyl urea. H base cream is a proprietary product produced by Professional Compounds Centers of America and licensed by it.
The mixture of imiquimod and H base cream as described above is administered transdermally, preferably by mixing ¼ cc ALDARA™ 5% cream with ¼ cc H base cream and applying the resulting mixture to various locations, i.e., the inner thigh, abdomen, hip, arms, etc., of the patient. Various sites of administration prevent any possible skin irritation. The foregoing amount of the mixture of ALDARA™ 5% cream and H base cream is applied daily.
- water, glycerin, canola oil, stearic acid, cetyl alcohol, PEG-100 stearate, glyceryl stearate, dimethicone, magnesium aluminum silicate, propylene glycol, triethanolamine, polysorbate 60, xanthan gum, bitter almond kernel oil, aloe vera, grape seed extract, wheat germ oil, vitamin E acetate, vitamin A palmitate, Vitamin C palmitate, tetrasodium EDTA, potassium sorbate, diazolidinyl urea. H base cream is a proprietary product produced by Professional Compounds Centers of America and licensed by it.
- Tumor necrosis factor (also called TNFa, cachexin, or cachetin) stimulates T-cells that coordinate the immune system. In a healthy human body, tumor necrosis factor is released by white blood cells and other tissues in response to damage caused by an infection. Tumor necrosis factor is found in several vaccines. The preferable vaccine to be used in accordance with the present invention is the BCG vaccine, which is a common vaccine for tuberculosis, given in the United States and around the world. The tumor necrosis factor included in the BCG vaccine and imiquimod, i.e. ALDARA™ cream, work together to stimulate the T-cells and coordinate and improve the patient's immune system. Interferon alpha coats the virus or infection in order to make the virus or infection vulnerable to the tumor necrosis factor.
- In accordance with the present invention, the vaccine is given in doses of 0.1 mL (100 μg) once every three weeks as long as the treatment continues. Valacyclovia hydrochlorine tablets, available from GlaxoSmithKline under the trademark Valtrex™ is drug commonly used in the treatment for genital herpes. In accordance with the present invention, Valtrex™ tablets are consumed twice daily in 500 mg doses. The combination of the ALDARA™ and H base cream, the BCG vaccination, and the Valtrex™ tablets is administered until a blood tumor cell count indicates that there are no cancer cells in the blood and a subsequent blood tumor cell count verifies a normal cell count and no mestastases are present. The results of the procedure are periodically monitored utilizing the Blood CA 27,29 testing procedure.
- Referring to
FIG. 3 thereof, persons with Type I diabetes must check their blood glucose levels at multiple intervals as directed by their physician. The average fasting blood glucose level should be between 70 mg/dL and 110 mg/dL. If the blood glucose level is not within the target level, the level must be corrected by taking insulin. - The diabetes treatment procedure of the present invention comprises the transdermal administration of the drug imiquimod combined with a BCG vaccination and administration of valacyclovia hydrochlorine tablets. Imiquimod is commercially available from 3M Pharmaceuticals under the trademark ALDARA™. A healthy human body produces the protein interferon alpha in response to an infection. Interferon alpha works to coat the infection or virus in order to make the infection or virus vulnerable to the human immune system. Imiquimod, i.e. ALDARA™ cream, turns into interferon alpha once inside the human body, providing the needed interferon alpha not adequately produced by the patient's own body.
- In accordance with the present invention, ALDARA™ cream 5% is mixed at a 1:1 ratio with H base cream. The ingredients of H base cream are:
-
- water, glycerin, canola oil, stearic acid, cetyl alcohol, PEG-100 stearate, glyceryl stearate, dimethicone, magnesium aluminum silicate, propylene glycol, triethanolamine, polysorbate 60, xanthan gum, bitter almond kernel oil, aloe vera, grape seed extract, wheat germ oil, vitamin E acetate, vitamin A palmitate, Vitamin C palmitate, tetrasodium EDTA, potassium sorbate, diazolidinyl urea. H base cream is a proprietary product produced by Professional Compounds Centers of America and licensed by it.
The mixture of imiquimod and H base cream as described above is administered transdermally, preferably by mixing ¼ cc ALDARA™ 5% cream with ¼ cc H base cream and applying the resulting mixture to various locations, i.e., the inner thigh, abdomen, hip, arms, etc., of the patient. Various sites of administration prevent any possible skin irritation. The foregoing amount of the mixture of ALDARA™ 5% cream and H base cream is applied daily.
- water, glycerin, canola oil, stearic acid, cetyl alcohol, PEG-100 stearate, glyceryl stearate, dimethicone, magnesium aluminum silicate, propylene glycol, triethanolamine, polysorbate 60, xanthan gum, bitter almond kernel oil, aloe vera, grape seed extract, wheat germ oil, vitamin E acetate, vitamin A palmitate, Vitamin C palmitate, tetrasodium EDTA, potassium sorbate, diazolidinyl urea. H base cream is a proprietary product produced by Professional Compounds Centers of America and licensed by it.
- Tumor necrosis factor (also called TNFa, cachexin, or cachetin) stimulates T-cells that coordinate the immune system. In a healthy human body, tumor necrosis factor is released by white blood cells and other tissues in response to damage caused by an infection. Tumor necrosis factor is found in several vaccines. The preferable vaccine to be used in accordance with the present invention is the BCG vaccine, which is a common vaccine for tuberculosis, given in the United States and around the world. The tumor necrosis factor included in the BCG vaccine and imiquimod, i.e. ALDARA™ cream, work together to stimulate the T-cells and coordinate and improve the patient's immune system. Interferon alpha coats the virus or infection in order to make the virus or infection vulnerable to the tumor necrosis factor.
- In accordance with the present invention, the vaccine is given in doses of 0.1 mL (100 μg) once every three weeks as long as the treatment continues. Valacyclovia hydrochlorine tablets, available from GlaxoSmithKline under the trademark Valtrex™ is drug commonly used in the treatment for genital herpes. In accordance with the present invention, Valtrex™ tablets are consumed twice daily in 500 mg doses.
- The results of the procedure are monitored utilizing blood sugar meters and a diary to record ongoing blood sugar levels. Additionally, A-1-C checks track the patient's overall blood sugar levels over two to three month periods, and is the most effective way to track long-range success of the treatment. The treatment method regenerates islet cells, which produce insulin. Once the patient no longer depends on insulin to correct blood sugar levels, the treatment continues until the patient has two or more sequential A-1-C checks in the target range, depending on the judgment of the treating physician. Once treatment is discontinued, A-1-C checks continue, but at less frequent intervals as recommended by the treating physician.
- Although preferred embodiments of the invention have been illustrated in the accompanying Drawings and described in the foregoing Detailed Description, it will be understood that the invention is not limited to the embodiments disclosed, but is capable of numerous rearrangements, modifications, and substitutions of parts and elements without departing from the spirit of the invention.
Claims (10)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/032,399 US20060062755A1 (en) | 2004-09-21 | 2005-01-10 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/133,838 US7125836B2 (en) | 2004-09-21 | 2005-05-19 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/261,849 US20060063213A1 (en) | 2004-09-21 | 2005-10-27 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/261,850 US20060062759A1 (en) | 2004-09-21 | 2005-10-27 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/292,662 US20060099172A1 (en) | 2004-09-21 | 2005-12-02 | Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza |
US11/533,805 US7507703B2 (en) | 2004-09-21 | 2006-09-21 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US12/100,089 US20080193482A1 (en) | 2004-09-21 | 2008-04-09 | Method of cancer screening; method of cancer treatment; and method of auto-immune disease treatment |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/946,213 US20060063211A1 (en) | 2004-09-21 | 2004-09-21 | Method of cancer screening and method of cancer treatment |
US11/003,293 US20060063212A1 (en) | 2004-09-21 | 2004-12-03 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/032,399 US20060062755A1 (en) | 2004-09-21 | 2005-01-10 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/946,213 Continuation-In-Part US20060063211A1 (en) | 2004-09-21 | 2004-09-21 | Method of cancer screening and method of cancer treatment |
US11/003,293 Continuation-In-Part US20060063212A1 (en) | 2004-09-21 | 2004-12-03 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/133,838 Division US7125836B2 (en) | 2004-09-21 | 2005-05-19 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/133,838 Continuation US7125836B2 (en) | 2004-09-21 | 2005-05-19 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/292,662 Continuation-In-Part US20060099172A1 (en) | 2004-09-21 | 2005-12-02 | Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060062755A1 true US20060062755A1 (en) | 2006-03-23 |
Family
ID=36074247
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/032,399 Abandoned US20060062755A1 (en) | 2004-09-21 | 2005-01-10 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/133,838 Expired - Fee Related US7125836B2 (en) | 2004-09-21 | 2005-05-19 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/261,850 Abandoned US20060062759A1 (en) | 2004-09-21 | 2005-10-27 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/261,849 Abandoned US20060063213A1 (en) | 2004-09-21 | 2005-10-27 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/533,805 Expired - Fee Related US7507703B2 (en) | 2004-09-21 | 2006-09-21 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/133,838 Expired - Fee Related US7125836B2 (en) | 2004-09-21 | 2005-05-19 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/261,850 Abandoned US20060062759A1 (en) | 2004-09-21 | 2005-10-27 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/261,849 Abandoned US20060063213A1 (en) | 2004-09-21 | 2005-10-27 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
US11/533,805 Expired - Fee Related US7507703B2 (en) | 2004-09-21 | 2006-09-21 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
Country Status (1)
Country | Link |
---|---|
US (5) | US20060062755A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080299100A1 (en) * | 2004-01-22 | 2008-12-04 | University Of Miami | Topical Co-Enzyme Q10 Formulations and Methods of Use |
WO2011069527A1 (en) * | 2009-12-09 | 2011-06-16 | Ulrich Freiherr Von Arnim | Treatment scheme for idd and other automimmune diseases |
US9896731B2 (en) | 2009-05-11 | 2018-02-20 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US9901542B2 (en) | 2013-09-04 | 2018-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
US10376477B2 (en) | 2011-04-04 | 2019-08-13 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US10668028B2 (en) | 2008-04-11 | 2020-06-02 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008526765A (en) * | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | Treatment of skin metastases |
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US20110021555A1 (en) | 2008-12-19 | 2011-01-27 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses |
US20110207766A1 (en) | 2009-07-13 | 2011-08-25 | Graceway Pharmaceuticals, Llc. | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US20120195911A1 (en) * | 2011-02-01 | 2012-08-02 | Artur Martynov | Method of treatment of cancer patients |
-
2005
- 2005-01-10 US US11/032,399 patent/US20060062755A1/en not_active Abandoned
- 2005-05-19 US US11/133,838 patent/US7125836B2/en not_active Expired - Fee Related
- 2005-10-27 US US11/261,850 patent/US20060062759A1/en not_active Abandoned
- 2005-10-27 US US11/261,849 patent/US20060063213A1/en not_active Abandoned
-
2006
- 2006-09-21 US US11/533,805 patent/US7507703B2/en not_active Expired - Fee Related
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8771680B2 (en) | 2004-01-22 | 2014-07-08 | University Of Miami | Topical co-enzyme Q10 formulations and methods of use |
US20080299100A1 (en) * | 2004-01-22 | 2008-12-04 | University Of Miami | Topical Co-Enzyme Q10 Formulations and Methods of Use |
US8147825B2 (en) | 2004-01-22 | 2012-04-03 | University Of Miami | Topical co-enzyme Q10 formulations and methods of use |
US8293227B2 (en) | 2004-01-22 | 2012-10-23 | University Of Miami | Topical co-enzyme Q10 formulations and methods of use |
US8562976B2 (en) | 2004-01-22 | 2013-10-22 | University Of Miami | Co-enzyme Q10 formulations and methods of use |
US8586030B2 (en) | 2004-01-22 | 2013-11-19 | University Of Miami | Co-enzyme Q10 formulations and methods of use |
US10668028B2 (en) | 2008-04-11 | 2020-06-02 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
US9896731B2 (en) | 2009-05-11 | 2018-02-20 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US10351915B2 (en) | 2009-05-11 | 2019-07-16 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10) |
US10519504B2 (en) | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
US11028446B2 (en) | 2009-05-11 | 2021-06-08 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
WO2011069527A1 (en) * | 2009-12-09 | 2011-06-16 | Ulrich Freiherr Von Arnim | Treatment scheme for idd and other automimmune diseases |
US10376477B2 (en) | 2011-04-04 | 2019-08-13 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US11452699B2 (en) | 2011-04-04 | 2022-09-27 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
US9901542B2 (en) | 2013-09-04 | 2018-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
US11298313B2 (en) | 2013-09-04 | 2022-04-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
Also Published As
Publication number | Publication date |
---|---|
US7507703B2 (en) | 2009-03-24 |
US7125836B2 (en) | 2006-10-24 |
US20060063213A1 (en) | 2006-03-23 |
US20060062759A1 (en) | 2006-03-23 |
US20070014821A1 (en) | 2007-01-18 |
US20060062757A1 (en) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7125836B2 (en) | Method of cancer screening; method of cancer treatment; and method of diabetes treatment | |
TW201615221A (en) | The new indication of the anti-inflammatory drugs | |
Alrawashdeh et al. | Lichen planus eruption following Oxford-AstraZeneca COVID-19 vaccine administration: a case report and review of literature | |
US20060062762A1 (en) | Method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment | |
EP4342475A1 (en) | Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient | |
Burzynski et al. | Long-term survival over 21 years and pathologically confirmed complete response in pediatric anaplastic astrocytoma: A case report | |
US20060099172A1 (en) | Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza | |
US20080193482A1 (en) | Method of cancer screening; method of cancer treatment; and method of auto-immune disease treatment | |
CN106163515A (en) | Anticancer and agents for relieving side effects | |
Wood et al. | Preliminary Safety of PDS0101 (Versamune+ HPVmix) and Pembrolizumab Combination Therapy in Subjects with Recurrent/Metastatic Human Papillomavirus-16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) | |
US20060063212A1 (en) | Method of cancer screening; method of cancer treatment; and method of diabetes treatment | |
EP0680756B1 (en) | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis | |
US20230065168A1 (en) | Vismodegib in combination with a replication-deficient type 5 adenovirus for expression of interferon gamma for the treatment of skin cancer | |
RU2524309C1 (en) | Method for selecting therapeutic approach to locally advanced prostate cancer | |
US20060062756A1 (en) | Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment | |
Deshmukh | Effectiveness of ayurvedic treatment in alleviating side-effects of radiotherapy in patients suffering from oropharyngeal cancer and its relationship with im-provement in immune status of the host | |
CN110494137B (en) | Mammalian target protein of rapamycin inhibitors and use of chloroquine in treating cancer | |
US20070128264A1 (en) | Method of cancer screening and method of cancer treatment | |
RU2241452C1 (en) | Method for treating osseous metastasis | |
Chamberlain et al. | Stereotactic radiosurgery for metastatic brain tumors | |
Nambiar et al. | 255. SENSITIVITY OF HEART RATE VARIABILITY IN DETECTING DIURNAL VARIATIONS OF DOṢA DOMINANCE e A PILOT STUDY | |
WO2021104034A1 (en) | Use of 4-hydroxybenzaldehyde in treating inflammatory bowel disease | |
Greiner et al. | Urticaria associated with a small cell carcinoma of the lung | |
RU2234962C2 (en) | Method for treating the cases of non-resectable pancreatic carcinoma | |
Murad et al. | Phase II trial of isotretinoin and interferon alpha-2a in the treatment of advanced recurrent cervical carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WOODWARD FAMILY LTD., A PARTNERSHIP OF THE STATE O Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WOODWARD, JOHN R.;REEL/FRAME:016165/0443 Effective date: 20050106 |
|
AS | Assignment |
Owner name: LES MEDECINS L.P., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WOODWARD FAMILY LTD., A PARTNERSHIP OF THE STATE OF TEXAS,;WOODWARD, JOHN R., GENERAL PARTNER;REEL/FRAME:016618/0131 Effective date: 20050303 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |